TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38776484

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 15 mg PO twice a day with paclitaxel/carboplatin chemotherapy
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard chemotherapy (paclitaxel/carboplatin)
Number of subjects: 147
Study: 38776498

Group type: EXPERIMENTAL
Intervention: COVID-19 public health intervention
Number of subjects: 0
Study: 38776515

Group type: EXPERIMENTAL
Intervention: Treatment options based on PROSPECT trial data
Number of subjects: 0
Study: 38776517

Group type: EXPERIMENTAL
Intervention: Artificial intelligence in diagnostic imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificial intelligence in prediction of outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificial intelligence in histopathology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificial intelligence in treatment planning
Number of subjects: 0
Study: 38776543

Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy (a specific intervention for root canal disinfection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 38776589

Group type: EXPERIMENTAL
Intervention: Mobile PASS service
Number of subjects: 418
Study: 38776635

Group type: EXPERIMENTAL
Intervention: Intervention M (influenza vaccine messaging platform: video, flyer, scripted message, vaccine acceptance question, provider notification)
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Intervention Q (no messaging, vaccine acceptance question, provider notification)
Number of subjects: 767

Group type: COMPARATOR
Intervention: Control (usual care/no intervention)
Number of subjects: 767
Study: 38776640

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3445

Group type: COMPARATOR
Intervention: Noncardiovascular death
Number of subjects: 3445
Study: 38776754

Group type: EXPERIMENTAL
Intervention: Dietary sulfur amino acid restriction (SAAR) (∼2 g SAA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control diet (∼5.6 g SAA)
Number of subjects: 59
Study: 38776914

Group type: EXPERIMENTAL
Intervention: Iberdomide treatment
Number of subjects: 0
Study: 38777128

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semaglutide 0.5 mg (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide (all doses)
Number of subjects: 0
Study: 38777276

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) task
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Feeling like punishing oneself
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Baseline symptom factor
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Maudsley Staging Method treatment-resistance scores
Number of subjects: 98
Study: 38777289

Group type: EXPERIMENTAL
Intervention: High and Consistent Anxiety group
Number of subjects: 117
Study: 38777393

Group type: COMPARATOR
Intervention: Community-based NCD screening and management programme in Indonesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community-based NCD screening and management programme in Viet Nam
Number of subjects: 0
Study: 38777422

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Programmed exercise
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: BCAA supplementation and programmed exercise
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 220
Study: 38777421

Group type: EXPERIMENTAL
Intervention: Refeeding syndrome diagnosed using traditional criterion (TC)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Refeeding syndrome diagnosed using Friedli consensus recommendations
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Refeeding syndrome diagnosed using ASPEN criteria
Number of subjects: 85

Group type: COMPARATOR
Intervention: Patients without refeeding syndrome
Number of subjects: 85
Study: 38777473

Group type: EXPERIMENTAL
Intervention: Multidisciplinary transitional nutritional intervention
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 130
Study: 38777559

Group type: EXPERIMENTAL
Intervention: Recommendation and a text-based intervention aimed at generating intention and motivation to get screened
Number of subjects: 114

Group type: COMPARATOR
Intervention: Recommendation for CRC screening only
Number of subjects: 114
Study: 38777585

Group type: EXPERIMENTAL
Intervention: Coproduction approach, process of coproduction, multi-sector stakeholder group, possibility of active participation, coordinating role of researchers, communication, atmosphere and interaction
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Differences in roles and hierarchy, merging of different perspectives, clarification of intervention costs, competition and conflicting interests
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Coproduction method
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Effective management of power differences among stakeholders
Number of subjects: 7
Study: 38777939

Group type: EXPERIMENTAL
Intervention: Modified fasting with dietary and lifestyle modifications
Number of subjects: 114
Study: 38778036

Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR)
Number of subjects: 87
Study: 38778211

Group type: EXPERIMENTAL
Intervention: CYP-001 (iPS cell-derived mesenchymal stromal cells)
Number of subjects: 15
Study: 38778264

Group type: EXPERIMENTAL
Intervention: Morning light treatment for 4 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) for 4 weeks
Number of subjects: 68
Study: 38778289

Group type: EXPERIMENTAL
Intervention: Individualized exercise guidance
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 312
Study: 38778292

Group type: EXPERIMENTAL
Intervention: Persian version of the Low Physical Activity Questionnaire (LoPAQ)
Number of subjects: 120
Study: 38778345

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention with self-monitoring of blood glucose (SMBG) combined with sleep and mental health monitoring
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention with SMBG, sleep and mental health monitoring, plus blood pressure and activity monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 60
Study: 38778383

Group type: EXPERIMENTAL
Intervention: 9-week web-based group training guided by a facilitator
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 9-week web-based self-help training
Number of subjects: 150

Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 150
Study: 38778416

Group type: EXPERIMENTAL
Intervention: Early progressive mobilization (EPM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Early progressive upright positioning (EPUP)
Number of subjects: 65
Study: 38778549

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg b.i.d.
Number of subjects: 1157
Study: 38778803

Group type: EXPERIMENTAL
Intervention: ECPR treatment
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 134
Study: 38778807

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation and aerobic exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38779539

Group type: EXPERIMENTAL
Intervention: Hominis placental (HPP) extract
Number of subjects: 82

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 82
Study: 38779575

Group type: EXPERIMENTAL
Intervention: Low-intensity robot-assisted gait training (RAGT) at progressively increasing intensity
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional robot-assisted gait training (RAGT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Overground gait training (OGT)
Number of subjects: 24
Study: 38779740

Group type: EXPERIMENTAL
Intervention: Defibrotide (25 mg/kg intravenously, divided into four daily doses over 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care only (control cohort)
Number of subjects: 0
Study: 38779911

Group type: EXPERIMENTAL
Intervention: Targeted treatments based on molecular profiling (24 drugs available)
Number of subjects: 1167
Study: 38780066

Group type: EXPERIMENTAL
Intervention: Restrictive RBC transfusion strategy
Number of subjects: 644
Study: 38780185

Group type: EXPERIMENTAL
Intervention: App-based mental training (MT) for 3 months, daily 10-minute sessions
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: App-based mental training (MT)
Number of subjects: 174
Study: 38780262

Group type: EXPERIMENTAL
Intervention: Cefepime-taniborbactam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 0
Study: 38780386

Group type: EXPERIMENTAL
Intervention: Telemedicine-supported early discharge program
Number of subjects: 19
Study: 38780434

Group type: EXPERIMENTAL
Intervention: ETDRS group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Landolt C group
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 38780446

Group type: EXPERIMENTAL
Intervention: Netarsudil
Number of subjects: 25
Study: 38780499

Group type: EXPERIMENTAL
Intervention: Living kidney donation
Number of subjects: 924

Group type: COMPARATOR
Intervention: Nondonors
Number of subjects: 924
Study: 38780528

Group type: EXPERIMENTAL
Intervention: Virtual Reality Mindfulness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerated Transcranial Magnetic Stimulation Protocol 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerated Transcranial Magnetic Stimulation Protocol 2
Number of subjects: 0
Study: 38780536

Group type: EXPERIMENTAL
Intervention: High-Frequency Transcranial Magnetic Stimulation
Number of subjects: 0
Study: 38780604

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 321
Study: 38780814

Group type: EXPERIMENTAL
Intervention: Foot plantar massage
Number of subjects: 70
Study: 38780927

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg IV every 2 weeks for 5 cycles during IMRT, then 480 mg IV every 4 weeks for a total of 52 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nivolumab during IMRT reirradiation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nivolumab and IMRT reirradiation
Number of subjects: 51
Study: 38780943

Group type: EXPERIMENTAL
Intervention: At-school vaccination
Number of subjects: 30739

Group type: COMPARATOR
Intervention: Education and motivation of adolescents
Number of subjects: 30739

Group type: COMPARATOR
Intervention: Training of GPs
Number of subjects: 30739

Group type: EXPERIMENTAL
Intervention: At-school vaccination with poor access to GPs
Number of subjects: 30739

Group type: EXPERIMENTAL
Intervention: At-school vaccination with good access to GPs
Number of subjects: 30739
Study: 38780948

Group type: EXPERIMENTAL
Intervention: SZMN block group (n=26)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (n=27)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study: 38780953

Group type: EXPERIMENTAL
Intervention: OCTA metrics (Skeletonized Vessel Density and Perfusion Density) and Color Fundus Photography (CFP) images
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Microaneurysm turnover analysis
Number of subjects: 122
Study: 38780959

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combined Airway and Positional Therapy (CAPT)
Number of subjects: 50
Study: 38780960

Group type: EXPERIMENTAL
Intervention: Multilevel intervention (6-month patient-level lay health worker structured ACP education + clinician-level intervention with 3-hour ACP training and structured electronic health record documentation template)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Multilevel intervention
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control group (clinician-level intervention alone)
Number of subjects: 402
Study: 38780998

Group type: EXPERIMENTAL
Intervention: AR-based educational program
Number of subjects: 28
Study: 38781006

Group type: EXPERIMENTAL
Intervention: iCPR CDS-based intervention for registered nurses (RNs)
Number of subjects: 43
Study: 38781010

Group type: EXPERIMENTAL
Intervention: Suicide Prevention by Peers Offering Recovery Tactics (SUPPORT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Peer specialist training
Number of subjects: 11
Study: 38781013

Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or standard treatment)
Number of subjects: 0
Study: 38781043

Group type: EXPERIMENTAL
Intervention: Intraoperative frozen section (FS) diagnosis
Number of subjects: 935
Study: 38781168

Group type: EXPERIMENTAL
Intervention: Multimedia educational videos with evidence-informed design principles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimedia educational videos without evidence-informed design principles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 38781315

Group type: EXPERIMENTAL
Intervention: Acalabrutinib, venetoclax, and rituximab (AVR)
Number of subjects: 21
Study: 38781350

Group type: EXPERIMENTAL
Intervention: Computerized history taking software (CHT)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Physician-acquired medical history (EHR)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Agreement between CHT and EHR
Number of subjects: 1000
Study: 38781428

Group type: EXPERIMENTAL
Intervention: Secondary mitral regurgitation (MR) with MR volume ≥ 24 mL
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Secondary mitral regurgitation (MR) with MR fraction ≥ 30%
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Increasing RV ejection fraction (RVEF)
Number of subjects: 241

Group type: COMPARATOR
Intervention: RV dysfunction (RVEF < 45%)
Number of subjects: 241
Study: 38781564

Group type: EXPERIMENTAL
Intervention: CAR-37 T cells
Number of subjects: 5
Study: 38781591

Group type: EXPERIMENTAL
Intervention: Active treatment (maintained on antihypertensive therapy with a goal BP below 140/90 mm Hg)
Number of subjects: 2284
Study: 38781593

Group type: EXPERIMENTAL
Intervention: 24-hour mifepristone-to-misoprostol interval
Number of subjects: 80

Group type: COMPARATOR
Intervention: 12-hour mifepristone-to-misoprostol interval
Number of subjects: 80
Study: 38781634

Group type: EXPERIMENTAL
Intervention: Contraceptive switching or discontinuation
Number of subjects: 4289

Group type: EXPERIMENTAL
Intervention: Continuing with baseline method
Number of subjects: 4289

Group type: EXPERIMENTAL
Intervention: Method change (switching or discontinuing)
Number of subjects: 4289

Group type: EXPERIMENTAL
Intervention: Both switching and discontinuation
Number of subjects: 4289

Group type: EXPERIMENTAL
Intervention: Discontinuation
Number of subjects: 4289

Group type: EXPERIMENTAL
Intervention: Subsequent method after discontinuation
Number of subjects: 4289
Study: 38781664

Group type: EXPERIMENTAL
Intervention: Chlorthalidone/amiloride 25/5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 0
Study: 38781965

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) treatment, with or without chemotherapy, for front-/subsequent-line therapy.
Number of subjects: 3288

Group type: EXPERIMENTAL
Intervention: DT10-predicted-DCB patients
Number of subjects: 3288

Group type: EXPERIMENTAL
Intervention: DT10-predicted-NDB (non-durable benefit) group
Number of subjects: 3288
Study: 38782015

Group type: EXPERIMENTAL
Intervention: Arimoclomol citrate 1200 mg/day (400 mg three times per day)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Arimoclomol
Number of subjects: 239
Study: 38782091

Group type: EXPERIMENTAL
Intervention: Hands-on technique at the time of delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hands-off technique at the time of delivery
Number of subjects: 0
Study: 38782118

Group type: EXPERIMENTAL
Intervention: Multi-region sampling approach
Number of subjects: 123
Study: 38782232

Group type: EXPERIMENTAL
Intervention: Mindfulness and motivational interviewing-oriented physical-psychological integrated intervention (n=36)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (didactic education on lifestyle discussions and general health suggestions) (n=36)
Number of subjects: 72
Study: 38782542

Group type: EXPERIMENTAL
Intervention: EVX-01 (personalized peptide-based neoantigen vaccine)
Number of subjects: 12
Study: 38782549

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 3691

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 3691
Study: 38782609

Group type: EXPERIMENTAL
Intervention: Crushed venetoclax tablets
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ground venetoclax tablets
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intact venetoclax tablets
Number of subjects: 15
Study: 38782726

Group type: EXPERIMENTAL
Intervention: Volenrelaxin (intravenous or subcutaneous)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Volenrelaxin (subcutaneous once weekly for 5 weeks)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Volenrelaxin
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 38782968

Group type: EXPERIMENTAL
Intervention: Shear wave elastography (SWE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Qualitative B-mode cranial ultrasound (cUS)
Number of subjects: 90
Study: 38783176

Group type: EXPERIMENTAL
Intervention: MAF capsules
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: M capsules
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard of care (SOC) only
Number of subjects: 204
Study: 38783205

Group type: EXPERIMENTAL
Intervention: Multimodal treatment program over 24 weeks
Number of subjects: 915
Study: 38783238

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) maintenance therapy discontinued early after achieving CR/PR
Number of subjects: 80
Study: 38783268

Group type: EXPERIMENTAL
Intervention: Early pathophysiology-driven airway pressure release ventilation (APRV)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Low tidal volume ventilation (LTV)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: APRV
Number of subjects: 840

Group type: COMPARATOR
Intervention: LTV
Number of subjects: 840
Study: 38783296

Group type: EXPERIMENTAL
Intervention: Smartphone arm (e-mail transmission of photographs)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care arm (standard referral practice)
Number of subjects: 250
Study: 38783301

Group type: EXPERIMENTAL
Intervention: For-profit healthcare facilities
Number of subjects: 8941

Group type: EXPERIMENTAL
Intervention: Micropolitan location
Number of subjects: 8941
Study: 38783312

Group type: EXPERIMENTAL
Intervention: CeraTip™ depigmentation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Scalpel depigmentation
Number of subjects: 8
Study: 38783322

Group type: EXPERIMENTAL
Intervention: Group-based psychoeducation (6 sessions of 2 hours each)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Group-based psychoeducation
Number of subjects: 200
Study: 38783367

Group type: EXPERIMENTAL
Intervention: Dyspnea-VAS (visual analog scale)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Intubation
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Moderate dyspnea (dyspnea-VAS 40-64 mm)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Severe dyspnea (dyspnea-VAS ≥ 65 mm)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Systolic arterial pressure
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: 90-day mortality
Number of subjects: 310
Study: 38783390

Group type: EXPERIMENTAL
Intervention: Intrathecal MSC-NPs
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 54
Study: 38783427

Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 22

Group type: COMPARATOR
Intervention: Gluma
Number of subjects: 22
Study: 38783836

Group type: EXPERIMENTAL
Intervention: Computer-Based Training for Cognitive Behavioural Therapy (CBT4CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (TAU)
Number of subjects: 0
Study: 38783863

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline measurement
Number of subjects: 16
Study: 38783987

Group type: EXPERIMENTAL
Intervention: Emicizumab
Number of subjects: 504
Study: 38784165

Group type: EXPERIMENTAL
Intervention: Mobile app-based self-guided psychological intervention (Nałogometr 2.0) incorporating mindfulness techniques and Cognitive Behavioral Therapy (CBT) principles over three months.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile app-based self-guided psychological intervention (Nałogometr 2.0)
Number of subjects: 0
Study: 38784572

Group type: EXPERIMENTAL
Intervention: COVID-19 lockdown measures
Number of subjects: 48
Study: 38784617

Group type: EXPERIMENTAL
Intervention: LIFEwithIBD intervention (Acceptance and Commitment Therapy and compassion-based intervention)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: LIFEwithIBD intervention
Number of subjects: 355
Study: 38784791

Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Number of subjects: 0
Study: 38784916

Group type: EXPERIMENTAL
Intervention: Transcranial pulse stimulation (TPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham TPS
Number of subjects: 30
Study: 38784965

Group type: EXPERIMENTAL
Intervention: Behavioural change techniques delivered alongside an exercise programme
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (multidisciplinary education, supervised exercise class, prescribed home exercise program)
Number of subjects: 20
Study: 38785084

Group type: EXPERIMENTAL
Intervention: FFR-guided strategy
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Angiography-guided strategy
Number of subjects: 1163
Study: 38785209

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 3533
Study: 38785259

Group type: EXPERIMENTAL
Intervention: PSMA-PET
Number of subjects: 50

Group type: COMPARATOR
Intervention: mpMRI
Number of subjects: 50